Mersana Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 56.16 million compared to USD 47.26 million a year ago. Basic loss per share from continuing operations was USD 0.52 compared to USD 0.59 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.615 USD | -5.60% | +0.96% | +13.58% |
May. 09 | Transcript : Mersana Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $9.2M, vs. Street Est of $8.5M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.58% | 339M | |
+8.42% | 115B | |
+13.01% | 107B | |
-13.61% | 22.31B | |
-3.99% | 21.6B | |
-5.89% | 18.23B | |
-39.93% | 17.62B | |
+7.54% | 14.26B | |
+33.32% | 12.37B | |
-28.24% | 8.28B |
- Stock Market
- Equities
- MRSN Stock
- News Mersana Therapeutics, Inc.
- Mersana Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023